Semaglutide vs. Tirzepatide: How to Choose
If you're comparing GLP-1 options in North Carolina, South Carolina, Georgia, or Florida, the first real decision most patients face is which medication to start with. Compounded semaglutide and compounded tirzepatide are both effective, but they work a little differently — and those differences matter when you're choosing a starting point with your prescribing clinician.
How Semaglutide and Tirzepatide Work
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut naturally produces, which slows digestion, reduces appetite, and improves insulin signaling.
Tirzepatide takes that mechanism a step further. It's a dual GIP and GLP-1 receptor agonist, meaning it activates two hormone pathways instead of one. In practice, that dual action tends to produce stronger appetite suppression and more pronounced metabolic effects for many patients.
Both medications are available through Bold You Wellness as compounded preparations. Compounded semaglutide and tirzepatide are prepared by FDA-registered 503A and 503B compounding pharmacies — they are not FDA-approved finished drug products, but they use the same active pharmaceutical ingredients as their brand-name counterparts, prescribed under a licensed physician's medical judgment following a telehealth consultation.
Comparing Average Weight Loss
Clinical trial data gives a useful baseline, even though individual results vary:
- In the STEP-1 trial (NEJM, 2021), patients on semaglutide averaged 14.9% body weight loss over 68 weeks.
- In the SURMOUNT-1 trial (NEJM, 2022), patients on tirzepatide averaged 22.5% body weight loss over 72 weeks.
These numbers come from controlled clinical trial settings, not typical real-world results — adherence, starting weight, lifestyle factors, and individual metabolic response all affect outcomes. But directionally, tirzepatide's dual-hormone mechanism is generally associated with a larger average effect size than semaglutide alone.
Why the Gap Exists
The extra GIP pathway tirzepatide activates appears to add an additive effect on appetite regulation and energy metabolism beyond what GLP-1 activation alone produces. That's the leading explanation for the difference in average outcomes between the two trials, though head-to-head comparisons are still an active area of research.
Typical Side Effect Profiles
Both medications share a similar early side effect pattern, since they work through overlapping hormone pathways.
Common Early Side Effects
- Mild nausea, especially during dose increases
- Constipation or changes in bowel habits
- Reduced appetite (the intended effect, but noticeable)
- Occasional fatigue in the first 1–2 weeks
What Tends to Differ Between the Two
Some patients report that tirzepatide's dual mechanism produces a somewhat different GI side effect pattern than semaglutide alone, though both are generally manageable with slow dose titration — a schedule your provider builds around your tolerance. If you're weighing side effect sensitivity heavily, that's a specific, worthwhile thing to raise during intake, and we cover what that first stretch typically looks like in what to expect in your first month on GLP-1s.
Questions to Discuss With Your Clinician
There's no universal right answer between the two — the better fit depends on your health profile, goals, and how your body responds. Worth bringing to your consultation:
- Do I have elevated A1C, insulin resistance, or PCOS that might favor tirzepatide's dual mechanism?
- How does my starting weight and weight-loss goal affect which option makes more sense?
- What does the dose titration schedule look like for each, and how will my coach and provider adjust it?
- Are there cost or availability differences between the two in my state?
Your provider will walk through your intake and recommend a starting point based on your individual profile — this isn't a decision you have to make alone.
All claims and program benefits referenced on this site reflect self-reported data from patients on Bold You Wellness treatment plans. Clinical data cited above (STEP-1: 14.9% weight loss on semaglutide at 68 weeks; SURMOUNT-1: 22.5% weight loss on tirzepatide at 72 weeks) reflects outcomes in controlled clinical trial settings and is not representative of typical patient experience. Compounded medications referenced are prepared by FDA-registered 503A and 503B compounding pharmacies and are not FDA-approved finished drug products. Results vary. Not all patients will qualify.
Ready to see which option your provider recommends? Explore the Bold You Wellness weight loss program or check current pricing to get started.